Program
Program THURSDAY
|
16:00 – 16:30
Singapore
General
|
Welcome to Basel - welcome to the joint meeting of ICHS and SSAI
Hans H. Hirsch, Basel (CH) / Mike Recher, Basel (CH)
|
|
Infection and Immunity: Patient's perspective
Franziska Riner, Lenzburg (CH) / Stefan Eggimann, Küssnacht am Rigi (CH)
|
||
|
16:30 – 18:00
Singapore
Joint Session
|
Plenary Session 1: Infection and immunity – Are you competent?
Hans H. Hirsch, Basel (CH) / Mike Recher, Basel (CH)
|
|
Allergic diseases as inborn errors of immunity
Josh Milner, New York (US)
|
||
Infectious diseases in 2022
Annelies Zinkernagel, Zurich (CH)
|
||
Infection and Immunity: The Challenge of Safe Xenotransplantation
Jay Fishman, Boston (US)
|
||
|
18:00 – 18:45
Exhibition
General
|
Evening Reception (Industry Exhibition) |
|
Program FRIDAY
|
07:00 – 08:00
General
|
Registration and Room Finding |
|
|
08:00 – 08:50
Montreal
ICHS Session
|
MEET THE EXPERT 1Clinical and diagnostic considerations in immunocompetent vs immunodeficient patients (case-based) |
|
When Imaging goes viral…Focus on Corona, CARVs and CMV
Jens Bremerich, Basel (CH)
|
||
Clinical, diagnostic and functional integration: The lung expert‘s view
Daiana Stolz, Basel (CH)
|
||
|
08:00 – 08:50
Singapore
ICHS Session
|
MEET THE EXPERT 2Epidemiology and management of infections with new therapies in heme-onc and HCT (case-based) |
|
The new –nib on the block
Benjami W. Teh, Melbourne (AU)
|
||
The new block on the -mab
Johan Maertens, Leuven (BE)
|
||
|
08:00 – 08:50
Sydney
SSAI Session
|
MEET THE EXPERT 3: Meet the AllergologistImmediate type allergy |
|
Food Allergy, what‘s new?
Barbara Ballmer, St.Gallen (CH)
|
||
Understanding antibiotic allergy
Kathrin Scherer Hofmaier, Aarau (CH)
|
||
|
08:00 – 08:50
Osaka/Samarkand
SSAI Session
|
MEET THE EXPERT 4: Meet the translational immunologistTargeted treatment based on molecular mechanisms - Meet the translational immunologist |
|
... in the immunodeficient patient
Mike Recher, Basel (CH)
|
||
... in immune-oncology
Heinz Läubli, Basel (CH)
|
||
|
08:50 – 09:00
General
|
Time for Room Change |
|
|
09:00 – 10:00
Singapore
Joint Session
|
Plenary Session 2: When too little immunity turns bad… Session dedicated to Dr. Robert Finberg
Roy Chemaly, Houston (US) / Mario Fernández-Ruiz, Madrid (ES)
|
|
When immunodeficiency looks like infection...
Steven Holland, Bethesda (US)
|
||
When infection looks like immunodeficiency
Jay Fishman, Boston (US)
|
||
|
10:00 – 10:30
General
|
COFFEE BREAK / POSTER WALK (Posters / Industry Exhibition) |
|
|
10:30 – 11:50
Montreal
ICHS Session
|
Parallel Session 1: Invasive Fungal InfectionsRisk, and drugs and personalized medicine
Murat Akova, Ankara (TR) / Tobias Hohl, New York (US)
|
|
When things get “IFI” – clinical clues in heme-onc, HCT, and SOT
Nina Khanna, Basel (CH)
|
||
Is pre-emptive anti-fungal therapy ready for prime time ?
Johan Maertens, Leuven (BE)
|
||
Genetic risk stratifiers: Pentraxin paradigm and what’s in the pipeline
Pierre-Yves Bochud, Lausanne (CH)
|
||
New drugs, new goals, new guidelines
Monica Slavin, Melbourne (AU)
|
||
|
10:30 – 11:50
Singapore
ICHS Session
|
Parallel Session 2: Big DataAI for Diagnosis, Risk factors and Treatment Outcomes
Andri Rauch, Berne (CH) / Karoline Leuzinger, Basel (CH)
|
|
The Swiss Cohort Studies: Track record and way forward
Nicolas Müller, Zurich (CH)
|
||
The Swiss Personalized Health initiative
Adrian Egli, Zurich (CH)
|
||
Platform to evaluate outcomes for immunodysfunctional patients: PERSIMUNE
Jens Lundgren, Copenhagen (DK)
|
||
Transforming healthcare with the iBox prediction system
Marc Raynaud, Paris (FR)
|
||
|
10:30 – 11:50
Sydney
SSAI Session
|
Parallel Session 3: Myeloid cell dysregulation
Lukas Jörg, Berne (CH)
|
|
Mastocytosis: Clinical manifestations and novel treatment strategies
Karin Hartmann, Basel (CH)
|
||
Eosinophilic airway diseases: basic science, clinical manifestations and future challenges
Celeste Porsbjerg, Copenhagen (DK)
|
||
Histiocytic disorders
Julien Haroche, Paris (FR)
|
||
Targeting "Don't eat me" signals to treat hematologic malignancies
Alexandre Theocharides, Zurich (CH)
|
||
|
10:30 – 11:50
Osaka/Samarkand
SSAI Session
|
Parallel Session 4: Infections in primary immunodeficiency
Thomas Hauser, Zurich (CH) / Mike Recher, Basel (CH)
|
|
Overview of primary immunodeficiencies – basics
Isabelle Meyts, Leuven (BE)
|
||
Primary immunodeficiency – Infectious clues and diagnosis
Nizar Mahlaoui, Paris (FR)
|
||
Clinical approach to the pediatric patient – etiological and antimicrobial treatment
Thomas Lehrnbecher, Frankfurt (DE)
|
||
Clinical approach to the adult patient – etiological and antimicrobial treatment
Peter Jandus, Geneva (CH)
|
||
|
11:50 – 12:00
General
|
Time for Room Change |
|
|
12:00 – 13:20
Sydney
Industry Symposia
|
Industry Lunch Symposium - sponsored by CSL Behring AG
Adrian Zürcher, (CH)
|
|
Burden of infection in SID
Peter Jandus, Geneva (CH)
|
||
SIDs in hemato-oncological situations
Sacha Zeerleder, Lucerne (CH)
|
||
Where will we see SIDs in the future?
Kirsten Wittke, Berlin (DE)
|
||
|
12:00 – 13:20
General
|
Lunch Break - (Posters / Industry Exhibition) |
|
|
12:00 – 13:20
Singapore
Industry Symposia
|
Industry Lunch Symposium - Supported by Independent Medical Education Grant from Takeda International
Robin Avery, Baltimore (US) / Hans H. Hirsch, Basel (CH)
|
|
Dancing with the Troll – The lab perspective
Karoline Leuzinger, Basel (CH)
|
||
Precise and Personalized is Best Against the CMV Troll - The SOT Perspective
Camille N. Kotton, Boston (US)
|
||
Taming the CytomegaloBeast: Tools in our Armamentarium – The HCT perspective
Roy Chemaly, Houston (US)
|
||
|
13:20 – 13:30
General
|
Time for Room Change |
|
|
13:30 – 15:00
Montreal
ICHS Session
|
Parallel Session 5: The BEST OF ICHSCORONA COMPETENCE
Nicolas Müller, Zurich (CH) / Malgorzata Mikulska, Genoa (IT)
|
|
Virology
Roy Chemaly, Houston (US)
|
||
Solid organ
Robin Avery, Baltimore (US)
|
||
HCT
Monica Slavin, Melbourne (AU)
|
||
Autoimmunity
Jose-Maria Aguado, Madrid (ES)
|
||
|
13:30 – 15:00
Singapore
ICHS Session
|
Parallel Session 6: Immunity is down - just jack it up
Thomas Lehrnbecher, Frankfurt (DE) / Camille N. Kotton, Boston (US)
|
|
Treating infections with check-point inhibitors?
Irene Cortese, Bethesda (US)
|
||
T-cell guided antiviral therapy – ready for use?
Oriol Manuel, Lausanne (CH)
|
||
Transfer of antigen-specific immune effectors – Just do it!
Patrizia Comoli, Pavia (IT)
|
||
Energy management in viral infection
Andreas Bergthaler, Vienna (AT)
|
||
|
13:30 – 15:00
Sydney
SSAI Session
|
Parallel Session 7: Laboratory Diagnostics
Ingmar Heijnen, Basel (CH) / Luca Bernasconi, Aarau (CH)
|
|
Donor-specific Antibodies: Why measure it and what we do about it
Stefan Schaub, Basel (CH)
|
||
A novel functional mast cell assay for the detection of allergies
Alexander Eggel, Berne (CH)
|
||
Clinical application of genetic testing in primary immunodeficiencies
Johannes Trück, Zurich (CH)
|
||
Anti-cytokine autoantibodies: When and how to measure?
Rainer Doffinger, Cambridge (GB)
|
||
|
13:30 – 15:00
Osaka/Samarkand
SSAI Session
|
Parallel Session 8: Experimental Immunology
Daniela Latorre, Zurich (CH) / Daniel Legler, Kreuzlingen (CH)
|
|
Immunometabolic regulation of T cell function
Christoph Hess, Basel (CH)
|
||
CD4 T cells Sans Frontières: division of labor in the lung
Carolyn King, Basel / Lausanne (CH)
|
||
Coronin 1, T cell homeostasis and immunity: Getting it just right
Jean Pieters, Basel (CH)
|
||
Eosinophil subsets in intestinal inflammation
Isabelle Arnold, Zurich (CH)
|
||
|
15:00 – 15:30
General
|
COFFEE BREAK / POSTER WALK (Posters / Industry Exhibition) |
|
|
15:30 – 17:00
Singapore
Joint Session
|
Plenary Session 3: When too much immunity turns bad… (Aberrant responses to microbes)
Mike Recher, Basel (CH) / Thomas F. Patterson, San Antonio (US)
|
|
Genetic Susceptibility to Epstein Barr virus infection
Alain Fischer, Paris (FR)
|
||
The human genetic and immunological determinants of life-threatening COVID-19
Jean-Laurent Casanova, New York (US)
|
||
|
17:00 – 17:15
General
|
Time for Room Change |
|
|
17:15 – 18:45
Singapore
Industry Symposia
|
Industry Afternoon Symposium - Current and future directions for the management of invasive fungal infections in immunocompromised patientssponsored by Mundipharma
Samir Agrawal, (GB)
|
|
Welcome and introduction
Samir Agrawal, (GB)
|
||
Importance of PK/PD: optimising antifungal drug dosing
Russell Lewis, (IT)
|
||
Key challenges in the clinical management of invasive candidiasis: the value of a patient-tailored approach
Jose-Maria Aguado, Madrid (ES)
|
||
Addressing unmet needs of the current treatment paradigm: novel antifungals in development
Frédéric Lamoth, (CH)
|
||
Questions and answers |
||
|
17:15 – 18:45
General
|
Posters / Industry Exhibition |
|
Program SATURDAY
|
07:00 – 08:00
General
|
Registration and Room Finding |
|
|
08:00 – 08:50
Montreal
ICHS Session
|
MEET THE EXPERT 5Microbe alarm before transplantation – You’re on call… (Case-based - When to treat, when to defer, when to reject…) |
|
...the SOT perspective
Paolo Grossi, Varese (IT)
|
||
...the HCT perspective…
Zenia Papanicolaou, New York (US)
|
||
|
08:00 – 08:50
Singapore
ICHS Session
|
MEET THE EXPERT 6How immunocompromised is your patient ? (case-based) |
|
Which clinical criteria inform my daily practice ?
Monica Slavin, Melbourne (AU)
|
||
Which specific or adjunctive tests can help to inform diagnosis and management?
Mario Fernández-Ruiz, Madrid (ES)
|
||
|
08:00 – 08:50
Sydney
SSAI Session
|
MEET THE EXPERT 7: Meet the AerobiologistsInfection and respiratory allergy |
|
Pollen exposure in allergic as well as non-allergic subjects increases the susceptibility to respiratory viral infection, including to SARS-CoV-2
Stefanie Gilles, Munich (DE)
|
||
Respiratory viral infection increases the risk of developing respiratory allergies
Marie-Charlotte Brüggen, Zurich (CH)
|
||
|
08:00 – 08:50
Osaka/Samarkand
SSAI Session
|
MEET THE EXPERT 8: Meet the Swiss Young Immunologists (SYIS)Next generation immunologists
Daniela Latorre, Zurich (CH) / Sinduya Krishnarajah, Zurich (CH)
|
|
Best SYIS abstract 1: Microbial triggering of myelin-specific immune cells in the gut drives central nervous system inflammation
Lena Siewert, Basel (CH)
|
||
Best SYIS abstract 2: The emerging role of autoreactive T cells in Guillain-Barré syndrome
Lenka Sukenikova, Zurich (CH)
|
||
Best SYIS abstract 3: Generating a Virus-Like Particles based vaccine against IgE
Zahra Gharailoo, Bern (CH)
|
||
Best SYIS abstract 4: A novel Virus-Like Particle platform for the treatment of peanut allergy: mechanistic insights
Pascal Krenger, Bern (CH)
|
||
|
08:50 – 09:00
General
|
Time for Room Change |
|
|
09:00 – 10:00
Singapore
Joint Session
|
Plenary Session 4: Corona and COVID19 2022: State-of the-Art in the third pandemic year after start - (Session dedicated to Dr. Francisco Marty)
Monica Slavin, Melbourne (AU) / Hans H. Hirsch, Basel (CH)
|
|
SARS-CoV-2 and COVID19 – Clinical trials, real-time translation and way forward
Lindsey R. Baden, Boston (US)
|
||
The origin and ongoing evolution of SARS-CoV-2
Eddie Holmes, Sydney (AU)
|
||
|
10:00 – 10:30
General
|
COFFEE BREAK / POSTER WALK (Posters / Industry Exhibition) |
|
|
10:30 – 11:50
Montreal
ICHS Session
|
Parallel Session 9: Bacterial Infections, Immune dysfunction and critical illness
Nina Khanna, Basel (CH) / Mario Fernández-Ruiz, Madrid (ES)
|
|
Sepsis State-of-the-Art and what is unique to the immunocompromised host?
Thierry Calandra, Lausanne (CH)
|
||
Breaches in defence: catheters, ports and implants post-transplant
Paolo Grossi, Varese (IT)
|
||
MDR-bugs in heme-onc and HCT: Selection, scare and stewardship
Murat Akova, Ankara (TR)
|
||
MDR-bugs in solid organ transplantation: Who is at risk and why?
Jose-Maria Aguado, Madrid (ES)
|
||
|
10:30 – 11:50
Singapore
ICHS Session
|
Parallel Session 10: Community-acquired respiratory viruses in Immunocompromised Hosts
Maddalena Peghin, Varese (IT) / Laurent Kaiser, Geneva (CH)
|
|
CARV pathogenesis – clues from the good, the bad, and the ugly
Chrysanthi Skevaki, Giessen (DE)
|
||
How do I manage CARVs in solid organ transplant recipients?
Mike Ison, Chicago (US)
|
||
How do I manage CARVs in heme-onc and HCT?
Marie von Lilienfeld-Toal, Jena (DE)
|
||
Perspective: Infection control, and then what: antivirals, vaccines or immunotherapy ?
Roy Chemaly, Houston (US)
|
||
|
10:30 – 11:50
Sydney
SSAI Session
|
Parallel Session 11: The immunodysregulated skin
Alexander Navarini, Basel (CH)
|
|
Disseminated Papillomavirus Warts
Vivien Béziat, Paris (FR)
|
||
Atopic dermatitis
Patrick M. Brunner, Vienna (AT)
|
||
Skin manifestations in autoinflammatory diseases
Sinisa Savic, Leeds (GB)
|
||
T cells in the skin: Lymphoma and inflammatory skin disease
Christoph Schlapbach, Berne (CH)
|
||
|
10:30 – 11:50
Osaka/Samarkand
SSAI Session
|
Parallel Session 12: Epstein-Barr Virus and associated Diseases
Hiroyuki Yamamoto, Tokyo (JP) / Christoph Berger, Basel (CH)
|
|
Epstein-Barr Virus - Biology of invasion, stealth and resurrection
Christian Münz, Zurich (CH)
|
||
ADA2 deficiency: EBV lymphoproliferation and much more
Isabelle Meyts, Leuven (BE)
|
||
EBV diseases in transplantation
Cédric Hirzel, Berne (CH)
|
||
Novel inborn errors of immunity underlying susceptibility to EBV infection
Sylvain Latour, Paris (FR)
|
||
|
11:50 – 12:00
General
|
Time for Room Change |
|
|
12:00 – 13:20
Singapore
Industry Symposia
|
Industry Lunch Symposium - CMV in the Transplant Patient: What’s New?sponsored by MSD
Rafael de la Camara, Madrid (ES)
|
|
Confronting CMV in SOT: Complexities and Complications
Nassim Kamar, Toulouse (FR)
|
||
CMV in HSCT: Raising the Bar of Clinical Outcomes
Zenia Papanicolaou, New York (US)
|
||
What’s Next in Optimizing CMV Prevention: Emerging New Evidence
Michele Malagola, Brescia (IT)
|
||
Interactive Panel Discussion & Q&A |
||
|
12:00 – 13:20
Sydney
Industry Symposia
|
Industry Lunch Symposium - Vaccination in the immunocompromised patientsponsored by Moderna
Michel Obeid, Lausanne (CH)
|
|
mRNA science in response to a pandemic and potential beyond COVID-19
Melissa J. Moore
|
||
Protection of immunocompromised patients
Mike Ison, Chicago (US)
|
||
A trial platform for conducting nested trials of mRNA vaccine efficacy for SARS-CoV-2 in immune compromised hosts: The Swiss HIV and Transplant Cohort Studies
Heiner C. Bucher, Basel (CH)
|
||
Discussion and Q&A |
||
|
12:00 – 13:20
General
|
Lunch Break - (Posters / Industry Exhibition) |
|
|
13:20 – 13:30
General
|
Time for Room Change |
|
|
13:30 – 15:00
Montreal
ICHS Session
|
Parallel Session 13: Hepatitis Viruses - Direct and Indirect Challenges
Andri Rauch, Berne (CH) / Roberto Speck, Zurich (CH)
|
|
Transplantation with HCV – Milestones on the way to the new normal
Christine Durand, Baltimore (US)
|
||
Hepatitis E - Virology and clinical manifestations in the immunocompetent host
Darius Moradpour, Lausanne (CH)
|
||
Hepatitis E - Key lessons from Transplantation
Nassim Kamar, Toulouse (FR)
|
||
Hepatocellular cancer - mechanisms, personalized profiling and therapy approach
Markus Heim, Basel (CH)
|
||
|
13:30 – 15:00
Singapore
ICHS Session
|
Parallel Session 14: Best vaccination for Prevention, Control or Therapy
Lindsey R. Baden, Boston (US) / Maddalena Peghin, Varese (IT)
|
|
The Pandemic Challenge: Game-changer for respiratory viruses?
Natasha Halasa, Nashville (US)
|
||
The Reactivation challenge: CMV and other herpesviruses in patients at risk
Per Ljungman, Stockholm (SE)
|
||
The re-infection challenge: lessons from the malaria vaccine field
Claudia Daubenberger, Allschwil (CH)
|
||
The Cure Challenge: Mission impossible or breakthrough for HIV ?
Francesco Simonetti, Baltimore (US)
|
||
|
13:30 – 15:00
Sydney
SSAI Session
|
Parallel Session 15: Interferons: The good, the bad, the ugly
Camillo Ribi, Lausanne (CH) / Annette Oxenius, Zurich (CH)
|
|
The expanding spectrum of autoinflammatory interferonopathies and their mimics
Raphaela Goldbach-Mansky, Bethesda (US)
|
||
Priming systemic antiviral immunity by the gut microbiota
Nelson Gekara, Stockholm (SE)
|
||
What can we learn about type I interferons from murine models
Karl Lang, Essen (DE)
|
||
Type I and Type II Interferons in HLH
Jana Pachlopnik, Zurich (CH)
|
||
|
13:30 – 15:00
Osaka/Samarkand
SSAI Session
|
Parallel Session 16: Tumor immunology
Daniel Speiser, Lausanne (CH) / Martin Bachmann, Berne (CH)
|
|
Gut microbiota-immune crosstalk in neuroinflammation
Anne-Katrin Pröbstel, Basel (CH)
|
||
Revisiting the role of checkpoint molecule TIM-3 in cancer
Karen Dixon, Boston (US)
|
||
Biased Interleukin-2 immunotherapy against poorly-immunogenic and metastatic cancer
Onur Boyman, Zurich (CH)
|
||
Shielding Cells for Next Generation Cancer Immunotherapy
Lukas Jeker, Basel (CH)
|
||
|
15:00 – 15:15
General
|
Time for Room Change |
|
|
15:15 – 16:45
Sydney
Industry Symposia
|
Industry Afternoon Tea Symposium - CSU - (mis)perception and reality?sponsored by Novartis Pharma Schweiz AG
Peter Schmid-Grendelmeier, Zurich (CH)
|
|
How to deal with CSU? Optimal treatment for CSU patients
Peter Schmid-Grendelmeier, Zurich (CH)
|
||
The goals of treatment for CSU. How can we better support our CSU patients in terms of personalized medicine
Anna Gschwend, Bern (CH)
|
||
Where does CSU come from? New understandings in the CSU pathomechanism
François Spertini, Lausanne (CH)
|
||
|
15:15 – 16:45
Singapore
Industry Symposia
|
Industry Afternoon Tea Symposium - SAME SAME, BUT DIFFERENT – THE CHALLENGES OF SECONDARY IMMUNODEFICIENCYsponsored by Takeda Pharma AG
Oliver Hausmann, Lucerne (CH)
|
|
Welcome and Introduction
Oliver Hausmann, Lucerne (CH)
|
||
Disease-induced SID by Multiple Myeloma and Chronic Lymphocytic Leukemia
Cecilie Hveding Blimark, Gothenburg (SE)
|
||
Therapy-induced SID by CAR-T cell therapy
Antonia Müller, Vienna (AT)
|
||
Clinical Presentation and Management of SID
Sinisa Savic, Leeds (GB)
|
||
Closing
Oliver Hausmann, Lucerne (CH)
|
||
|
15:15 – 16:45
Montreal
Industry Symposia
|
Industry Afternoon Tea Symposium - Examining the immune response using the T-SPOT® technologysponsored by Oxford Immunotec |
|
Time for Prime Time: T-SPOT.CMV in HCT Recipients
Roy Chemaly, Houston (US)
|
||
Clinical implementation of CMV-specific CMI in solid organ transplantation
Oriol Bestard, Barcelona (ES)
|
||
Latent Tuberculosis testing in the Immunocompromised with ELISPOT
Johannes Nemeth, Zurich (CH)
|
||
|
16:45 – 16:55
General
|
Time for Room Change |
|
|
16:55 – 17:25
Montreal
ICHS Session
|
ICHS Lifetime achievements Award & Young investigator Award |
|
|
16:55 – 17:25
Osaka/Samarkand
SSAI Session
|
SSAI Awards (Best Posters for Biotest Awards, Sanofi Prize 2021 and Best SYIS presentation prize) |
|
|
17:25 – 17:35
General
|
Time for Room Change |
|
|
17:35 – 19:05
Montreal
ICHS Session
|
Parallel Session 17: Technical or Conceptual Game Changers in Laboratory Diagnostics (Swiss Society for Microbiology)
Gilbert Greub, Lausanne (CH) / Jean Villard, Geneva (CH)
|
|
What infectious disease clinicans caring for immunocompromised hosts wants from the lab...
Maddalena Peghin, Varese (IT)
|
||
Cell-free DNA and Virus replication: New concepts, challenges, and opportunities
Karoline Leuzinger, Basel (CH)
|
||
Comprehensive immune phenotyping - the Immunome: for whom, when and why?
Déla Golshayan, Lausanne (CH)
|
||
Metagenomics for Immunocompromised
Adrian Egli, Zurich (CH)
|
||
|
17:35 – 19:05
Singapore
ICHS Session
|
Parallel Session 18: Infections after Hematopoietic Cell Transplantation (ASTCT and EBMT-sponsored session)
Roy Chemaly, Houston (US) / Rafael de la Camara, Madrid (ES)
|
|
Cytokine relase syndrome: CAR-T cells or Sepsis?
Malgorzata Mikulska, Genoa (IT)
|
||
Rare Opportunistic Infections after HCT: Nocardiosis and Listeriosis
Dina Averbuch, Jerusalem (IL)
|
||
T cell Immunity, T cell Therapy and Viruses: What, when, and how?
Zenia Papanicolaou, New York (US)
|
||
COVID-19 in HCT Recipients: specific immune effectors or antivirals?
Sanjeet Dadhwal, Duarte (US)
|
||
|
17:35 – 19:05
Osaka/Samarkand
SSAI Session
|
SSAI General Assembly |
|
|
19:30 – 23:00
Joint Session
|
RHINE RIVER CRUISE NETWORKING EVENT |
|
Program SUNDAY
|
07:00 – 08:00
General
|
Registration and Room Finding |
|
|
08:00 – 08:50
Montreal
ICHS Session
|
MEET THE EXPERT 9The mighty mold – mechanisms, manifestations, management (Case-based) |
|
Mold biology and pathogenesis
Tobias Hohl, New York (US)
|
||
Clinical manifestations and management
Thomas Lehrnbecher, Frankfurt (DE)
|
||
|
08:00 – 08:50
Singapore
ICHS Session
|
MEET THE EXPERT 10 |
|
Do break points: from dilution and diffusion to Maldi-ToF AI
Adrian Egli, Zurich (CH)
|
||
Do break-proof: optimizing treatment of immunocompromised hosts
Malgorzata Mikulska, Genoa (IT)
|
||
|
08:00 – 08:50
Sydney
SSAI Session
|
MEET THE EXPERT 11: Meet the vaccinologistThe difficult to vaccine |
|
Vaccinations in immunodeficiency
Christoph Berger, Basel (CH)
|
||
Allergy to vaccines incl. COVID mRNA vaccines
Yannick Muller, Lausanne (CH)
|
||
|
08:00 – 08:50
Osaka/Samarkand
SSAI Session
|
MEET THE EXPERT 12: Meet the ENT specialistChronic rhinosinusitis |
|
Primary chronic rhinosinusitis
Simona Nicoleta Negoias, Basel (CH)
|
||
ANCA vasculitis, antibody deficiency etc.: Immunologic causes of chronic rhinosinusitis
Thomas Daikeler, Basel (CH)
|
||
|
08:50 – 09:00
General
|
Time for Room Change |
|
|
09:00 – 10:00
Singapore
Joint Session
|
Plenary Session 5: Novel insights into immune regulation, vaccination and immune therapy
Malgorzata Mikulska, Genoa (IT) / Manuel Battegay, Basel (CH)
|
|
The rationale for genetic and epigenetic causes for antibody deficiency
Bodo Grimbacher, Freiburg (DE)
|
||
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
|
||
BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy
|
||
|
10:00 – 10:30
General
|
COFFEE BREAK (Industry Exhibition) |
|
|
10:30 – 11:50
Singapore
Joint Session
|
ABSTRACTS AWARDSBest Abstracts of Infection & Immunity: What’s new and exciting? |
|
Exocrine gland-resident memory CD8+ T cells use mechanosensing for tissue surveillance
Nora Ruef, Fribourg (CH)
|
||
The cellular metabolism of SLE NK cells is primarily altered at the level of mitochondrial respiration.
Natalia Fluder, Lausanne (CH)
|
||
Development of a human in vitro lymphoid tissue model to study B cell responses
Elena Bonaiti, Basel (CH)
|
||
Molecular Characterization of BK Polyomavirus Replication in Allogeneic Hematopoietic Cell Transplantation
Karoline Leuzinger, Basel (CH)
|
||
COVID-19 Outcomes in Solid Organ Transplant Patients Given Tixagevimab-Cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-Led Program
Willa Cochran, Baltimore (US)
|
||
Improved outcomes over time and higher mortality in CMV seropositive allogeneic HCT patients with COVID-19; A study from the EBMT registry.
Per Ljungman, Stockholm (SE)
|
||
|
11:50 – 12:30
Singapore
Joint Session
|
CLOSING CEREMONY |
|
|
11:50 – 12:30
Singapore
General
|
FAREWELL & OUTLOOK
Mike Recher, Basel (CH) / Hans H. Hirsch, Basel (CH) / Murat Akova, Ankara (TR)
|
|
Color legend:
| SSAI SESSIONS |
| ICHS SESSIONS |
| JOINT SESSIONS |
| INDUSTRY SYMPOSIA |